REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, And/or Outbursts Associated with Dementia Due to Alzheimer's Disease)

Launched by OTSUKA PHARMACEUTICAL CO., LTD. · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called REXULTI to see how safe it is for people with Alzheimer's disease who may experience issues like excessive movement, aggression, or mood swings. The trial aims to gather information about how well the drug works in everyday medical settings.

To be eligible for this study, participants need to have a diagnosis of Alzheimer's disease. The trial is open to adults of all genders, starting from the age of 54 and up. If someone decides to participate, they will contribute to understanding how REXULTI can help manage certain challenging behaviors associated with Alzheimer's. It’s important to note that this trial is not yet recruiting participants, so there will be more details available once it starts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with Alzheimer's disease
• Exclusion Criteria:
• • -